)
Visual
test
Talphera
Talphera (TLPH) investor relations material
Talphera Registration filing summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.Registration filing summary25 Mar, 2026
Company overview and business model
Specialty pharmaceutical company focused on developing and commercializing innovative therapies for medically supervised settings, including acute care and dialysis-related products.
Product portfolio includes Niyad (regional anticoagulant for dialysis), LTX-608 (nafamostat for IV infusion), and two pre-filled syringe candidates (Fedsyra and phenylephrine).
Strategy centers on obtaining approval and commercializing Niyad, with plans to expand into additional acute care therapies.
Incorporated in Delaware, with a history of name changes and principal offices in San Mateo, CA.
Financial performance and metrics
Raised approximately $4.1 million in gross proceeds from the March 2025 private placement of common stock and pre-funded warrants.
As of March 16, 2026, 50,049,824 shares of common stock were issued and outstanding; no preferred stock outstanding.
Use of proceeds and capital allocation
Will not receive proceeds from the resale of shares by selling stockholders; all proceeds go to selling stockholders.
Partial view of Summaries dataset, powered by Quartr API
AI can get things wrong. Verify important information.Research faster. Power your platform.
Latest events from Talphera
- 50% enrollment milestone reached in NEPHRO CRRT study, unlocking $4.1M financing tranche.TLPH
Q4 2025 & Investor Day23 Mar 2026 - Q2 net loss narrowed, $14M cash, NEPHRO study expanded, but more funding needed soon.TLPHQ2 20241 Feb 2026
- Pivotal phase III trial of Niyad targets 2025 finish, with strong IP and market prospects.TLPHMaxim Group’s 2024 Healthcare Virtual Summit19 Jan 2026
- NEPHRO CRRT trial advances, net loss is $3.4M, and $11.1M cash on hand; more funding needed.TLPHQ3 202414 Jan 2026
- FDA-approved protocol changes and $14.8M financing support NEPHRO CRRT study completion.TLPHQ4 202424 Dec 2025
- Resale registration for shares and warrants from a private placement; no new capital raised.TLPHRegistration Filing16 Dec 2025
- Shares and warrants from a $17M private placement registered for resale; no proceeds to issuer.TLPHRegistration Filing16 Dec 2025
- Resale registration for shares and warrants from a $1.6M private placement; no proceeds to issuer.TLPHRegistration Filing16 Dec 2025
- Proxy covers director elections, equity plan changes, and a reverse split for Nasdaq compliance.TLPHProxy Filing1 Dec 2025
Next Talphera earnings date
Q1 202613 May, 2026
Talphera
Next Talphera earnings date
Q1 202613 May, 2026
The essential earnings season companion
The #1 app for qualitative research. Live earnings calls, AI chat, transcripts, and more. All for free.
Live calls and transcripts
Listen to earnings calls, CMDs, investor conferences, and more – with a podcast-like experience.
Find what you need faster
Search for any keyword across all transcripts simultaneously.
Easily store key findings
Capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Your watchlist. Your dashboard.
Follow the companies that matter to you. Get a personalized feed with real-time updates.
Be the first to know
Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned.
Consensus estimates
Access analyst consensus estimates, valuation multiples, and revenue segments splits.
All IR material in one place
The easiest way to stay updated during earnings season.
Global coverage
All events from public companies. Live and recorded.
Just click and listen
No webcast links. No manual registrations.
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
)
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
)
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
I can't remember the last time an app had such a positive impact on my investment process.
)
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
I can't remember the last time an app had such a positive impact on my investment process.
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
)
)
Frequently asked questions
Explore our global coverage